New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with

FIGARO-BM, an exploratory human biomarker study, provides additional insight on finerenone's mechanism of action in blocking mineralocorticoid receptor (MR) overactivation1New data presented at the American Society of Nephrology’s (ASN) Kidney Week 2023WHIPPANY, N.J.--(BUSINESS WIRE)--At the American Society of Neph...

Related Keywords

United States ,American ,Semin Nephrol ,Christian Rommel ,American Society Of Nephrology ,Clinical Trials Program ,Centers For Disease ,National Diabetes Statistics ,American Kidney Fund ,Bayer Healthcare Pharmaceuticals Inc ,National Institutes Of Health ,Head Of Research ,Facebook ,American Diabetes Association ,National Institute Of Diabetes ,American Association Of Clinical Endocrinology ,Twitter ,American Society ,Kidney Week ,Executive Committee ,Diabetic Kidney Disease ,Kerendia Phase ,American Diabetes ,American Association ,Kidney Disease ,Improving Global ,Prescribing Information ,Chronic Kidney Disease Associated ,Bayer Healthcare Pharmaceuticals ,Rev Dis ,Improving Global Outcomes ,Diabetes Statistics Report ,Its Burden ,Disease Control ,Accessed July ,Accessed May ,States Renal Data ,National Institutes ,National Institute ,Kidney Diseases ,